3 results
Approved WMOPending
To assess the safety of treatment with escalating dosages of VELCADE in combination with ZARNESTRA in subjects with Intermediate-2 or high risk MDS according to the IPSS classification.
Approved WMORecruiting
Since previous findings underline the hypothesis that ER may play a key role as an underlying mechanism leading to (re)victimisation, we suggest that a clinical intervention aimed at enhancing ER skills may decrease (re)victimisation risk. Therefore…
Approved WMOCompleted
Primary objective: To determine the antitumor activity regarding objective response rate (ORR) of tipifarnib in subjects with locally advanced non-resectable or metastatic, relapsed and/or refractory, non-haematological malignancies with HRAS…